Actinium Pharmaceuticals Inc. (Delaware) (ATNM)
NYSE: ATNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ATNM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $33.01M
- P/E (TTM)
- 2.44
- EPS (TTM)
- $0.43
- Dividend yield
- None
- 52-week range
- 0.735 – 1.72
- Day range
- 1.00 – 1.10
- Volume / Avg
- 280.66K / 193.83K
- Beta
- —
- Shares outstanding
- 31.44M
52-week range
ATNM stock today
On Nov 20, ATNM ended the session at $1.05, shedding $0.02 (1.87%), versus the S&P 500's 3.70% decline. At this level, ATNM sits in the middle of its 52-week range of $0.735 to $1.72: 39.0% below the high, set on Dec 22, 2025 and 42.9% above the low. ATNM is down 22.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 21.1%.
Actinium Pharmaceuticals (Delaware) trades at 2.4x its trailing twelve-month earnings per share of $0.43.
Summary generated from market data by MetaCap's automated system. Methodology
About Actinium Pharmaceuticals (Delaware)
Company profileActinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Sandesh C. Seth M.B.A., M.S.
- Headquarters
- New York, NY
- Employees
- 27
- Website
- actiniumpharma.com
Financial highlights
Full financialsIn fiscal 2025, Actinium Pharmaceuticals (Delaware) generated $90,000 in revenue. Actinium Pharmaceuticals (Delaware) reported a net loss of $33.9 million, compared with a loss of $38.2 million a year earlier. Operating margin was -40274.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $90.00K | — | $81.00K | $1.03M | $1.14M |
| Growth | — | — | -92.14% | -9.97% | — |
| Net income | $-33.89M | $-38.24M | $-48.82M | $-33.02M | $-24.77M |
| EPS (diluted) | $-1.09 | $-1.27 | $-1.83 | $-1.37 | $-1.20 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$3.60+242.86%
- Strong buy 1
- Buy 2
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-0.19 vs $-0.25
- Surprise
- +24.00%
ATNM news
All ATNM news- Actinium Pharmaceuticals Announces Inducement Grant to New EmployeePR Newswire
- Actinium Pharmaceuticals Announces Inducement Grants to New EmployeesPR Newswire
- Actinium Pharmaceuticals Names Matt David CFONasdaq
- Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerPR Newswire
Actinium Pharmaceuticals (Delaware) peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VERUVeru Inc. | 1.94 | -8.06% | $33.08M | vs ATNM |
| HYFTMindWalk Holdings Corp. | 0.6844 | -14.27% | $32.56M | vs ATNM |
| GRDXGridAI Technologies Corp. | 3.16 | -8.41% | $32.44M | vs ATNM |
| FLNAFilana Therapeutics Inc. | 0.6413 | +14.52% | $32.26M | vs ATNM |
| CUECue Biopharma Inc. | 4.15 | -7.78% | $34.69M | vs ATNM |
| GRCEGrace Therapeutics Inc. | 1.71 | -0.58% | $35.97M | vs ATNM |
| SERSerina Therapeutics Inc. | 1.12 | -6.67% | $29.76M | vs ATNM |
| NXTCNextCure Inc. | 6.45 | -4.87% | $29.53M | vs ATNM |
Indexes, lists and sector
Actinium Pharmaceuticals (Delaware) stock FAQ
What is Actinium Pharmaceuticals (Delaware)'s stock price today?
ATNM last traded at $1.05 as of Nov 20, 4:00 PM EST, down 1.87% on the day. Prices are delayed at least 15 minutes.
Does Actinium Pharmaceuticals (Delaware) pay a dividend?
No. Actinium Pharmaceuticals (Delaware) does not currently pay a regular cash dividend.
What is ATNM's P/E ratio?
ATNM trades at a trailing P/E ratio of 2.44.
Who is Actinium Pharmaceuticals (Delaware)'s CEO?
Mr. Sandesh C. Seth M.B.A., M.S. is the chief executive officer of Actinium Pharmaceuticals Inc. (Delaware), which has about 27 employees.
Has ATNM ever split its stock?
Yes. The most recent ATNM stock split was a 1-for-30 split on Aug 11, 2020.
What is the ATNM 52-week high?
The 52-week high for ATNM is $1.72 and the 52-week low is $0.735. The stock is currently 39.0% below its high.